论文信息 - Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule. - 字舞流文

Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule.

J. Verweij | G. Stoter | M. V. D. Van Der Burg | A. Planting | P. Beranek | M. van der Burg

[1] H. Pinedo,et al. Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in human ovarian cancer lines. , 1990, British Journal of Cancer.

[2] M. Perry. Chemotherapy, toxicity, and the clinician. , 1982, Seminars in oncology.

[3] M. Atkins,et al. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. , 1988, Pathology and immunopathology research.

[4] M. Perry,et al. Toxicity of chemotherapy , 1984 .

[5] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .